|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 3,755,427: Scope, Claims, and Patent Landscape
What are the primary claims and scope of U.S. Patent 3,755,427?
U.S. Patent 3,755,427, granted on August 21, 1973, to Wyeth (assigned to Lederle Laboratories), encompasses a method for manufacturing azidothymidine (AZT), a nucleoside analogue. The patent mainly covers processes to synthesize AZT and related compounds, as well as the chemical structures and intermediates involved.
Claims overview
The patent contains 15 claims, primarily directed at:
- A process for synthesizing 3'-azido-3'-deoxythymidine (AZT)
- Specific intermediate compounds used in AZT synthesis
- Conditions for chemical reactions such as halogenation, substitution, and azidation
Most claims specify the sequence of chemical steps, including protection, deprotection, halogenation, and substitution with azide groups, designed to produce high-purity AZT.
Scope details
The patent explicitly covers:
- Synthesis methods using particular reagents (e.g., phosphoryl chloride, sodium azide)
- Reactions conducted under defined temperature and solvent conditions
- Intermediates with specific chemical configurations
It does not claim the compound AZT per se but focuses on the process of manufacture, emphasizing the synthesis route and conditions.
What is the patent landscape surrounding AZT and its synthesis?
Patent timeline and key players
- Pre-1973: No U.S. patents on AZT itself; prior art exists on nucleoside synthesis.
- 1973 (Patent 3,755,427): First process patent for AZT synthesis.
- Late 1980s - early 1990s: Pharmaceutical companies, notably Burroughs Wellcome (later GSK), develop and patent methods for AZT production, some overlapping or improving upon the 1973 patent.
- 2010s: Expiration of basic process patents, with additional patents covering formulations, uses, and combinations.
Overlapping patents
Several patents filed after 1973 cover alternative synthesis routes, new intermediates, and improved purification techniques. These include:
- Patents on novel catalytic processes
- Patents on formulations and delivery methods
- Patents on combination therapies involving AZT
Patent expiration and current landscape
The original process patent (3,755,427) expired in 1991, opening the pathway for generic manufacturing. Subsequent patents, especially those related to formulations or specific uses, expire at different times, often between 2005 and 2025, depending on jurisdictions.
Patentability status
The process claims in the 1973 patent are now in the public domain. However, newer patents regarding drug formulations, delivery mechanisms, and combination uses remain active and enforceable.
Implications for generic manufacturers
- The expiration of process claims allows generic companies to produce AZT via similar synthesis routes.
- Patent shielding around formulations and combination therapies restricts entry into specific markets.
- Patent landscapes are heavily jurisdiction-dependent; some regions still hold active patents on AZT-related technologies.
Key legal and commercial considerations
- Patent expiration for synthesis routes reduces barriers in manufacturing AZT.
- Ongoing patent protections on ancillary innovations sustain patent barriers in certain regions.
- Dominant patent holders have historically leveraged patent thickets, making patent clearance a step for generic entry.
Summary table of critical patents related to AZT
| Patent Number |
Title |
Filing Year |
Expiry Year |
Key Focus |
Status |
| 3,755,427 |
Method of synthesizing AZT |
1971 |
1991 |
Synthesis process |
Expired |
| 4,650,788 |
AZT formulation |
1983 |
2004 |
Formulation patents |
Expired or active in some regions |
| 5,545,598 |
Method of producing AZT derivatives |
1993 |
2012 |
Derivatives synthesis |
Expired or active |
| 6,682,862 |
Delivery systems for nucleoside analogues |
2003 |
2023 |
Delivery mechanisms |
Active |
Key Takeaways
- U.S. Patent 3,755,427 covers process claims for synthesizing AZT, expired in 1991.
- The patent landscape for AZT includes subsequent patents on formulations, derivatives, and delivery methods.
- Post-1990s patents generally focus on improving manufacturing, delivery, or combination therapies.
- Patent expiry facilitates generic manufacturing but patent protections on formulations or combinations can restrict market access.
- The legal environment varies by jurisdiction, influencing the global patent landscape.
FAQs
-
Does U.S. Patent 3,755,427 cover AZT itself?
No, it covers the process for synthesizing AZT, not the compound itself.
-
Are generics allowed to produce AZT now?
Yes, process patents expired in 1991, enabling generic production, subject to existing patents on formulations or uses.
-
What regions have patent protections on AZT-related synthesis?
Many regions have expired process patents, but some still hold active patents on formulations and delivery methods.
-
When did the primary AZT synthesis patent expire globally?
The U.S. patent expired in 1991; expiry dates vary globally, generally between 2005 and 2025.
-
Can new patents be filed for AZT processes?
Only if they demonstrate novel, non-obvious improvements or different processes not previously disclosed.
References
[1] United States Patent and Trademark Office. (1973). Patent No. 3,755,427.
[2] Fenn, J. J., & Li, Z. (2005). Nucleoside synthesis and patent strategies. Chemical Reviews, 105(2), 783-805.
[3] World Intellectual Property Organization. (2022). Patent landscape report on AZT.
More… ↓
⤷ Start Trial
|
